Wolverine Trading, LLC Vaxart, Inc. Call Options Transaction History

Wolverine Trading, LLC

12 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$0.58 - $0.99 $57 - $99	100 Added 0.95%	10,600 $9,000
Q2 2024 Aug 14, 2024	BUY	$0.53 - $1.3 $5,565 - $13,650	10,500 New	10,500 $7,000
Q3 2023 Nov 15, 2023	BUY	$0.69 - $0.85 $1,380 - $1,700	2,000 Added 14.18%	16,100 $12,000
Q2 2023 Aug 23, 2023	BUY	$0.6 - $1.41 $8,460 - $19,881	14,100 New	14,100 $10,000
Q4 2022 Feb 14, 2023	SELL	$0.75 - $2.24 $10,275 - $30,688	-13,700 Reduced 30.24%	31,600 $30,000
Q3 2022 Nov 14, 2022	SELL	$2.09 - $4.5 $35,948 - $77,400	-17,200 Reduced 27.52%	45,300 $96,000
Q2 2022 Aug 15, 2022	SELL	$2.7 - $5.28 $14,310 - $27,984	-5,300 Reduced 7.82%	62,500 $220,000
Q1 2022 May 16, 2022	BUY	$4.29 - $6.64 $290,862 - $450,192	67,800 New	67,800 $338,000
Q4 2021 Feb 14, 2022	SELL	$5.77 - $7.96 $851,074 - $1.17 Million	-147,500 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$6.67 - $9.8 $325,496 - $478,240	-48,800 Reduced 24.86%	147,500 $1.18 Million
Q2 2021 Aug 06, 2021	BUY	$5.06 - $10.78 $359,766 - $766,458	71,100 Added 56.79%	196,300 $1.62 Million
Q1 2021 May 14, 2021	BUY	$5.64 - $23.33 $706,128 - $2.92 Million	125,200 New	125,200 $725,000

108

37.6M

188K

180K

Ticker VXRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 126,506,000
Market Cap $102M
Description
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1...

Get notified when there are updates to the investment portfolio of Wolverine Trading, LLC, based on Form 13F filings with the SEC.

Stay updated on Wolverine Trading, LLC with notifications on news.